311 related articles for article (PubMed ID: 34483003)
1. Therapeutic and prognostic insights from the analysis of cancer mutational signatures.
Brady SW; Gout AM; Zhang J
Trends Genet; 2022 Feb; 38(2):194-208. PubMed ID: 34483003
[TBL] [Abstract][Full Text] [Related]
2. Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity.
Smeby J; Kryeziu K; Berg KCG; Eilertsen IA; Eide PW; Johannessen B; Guren MG; Nesbakken A; Bruun J; Lothe RA; Sveen A
EBioMedicine; 2020 Sep; 59():102923. PubMed ID: 32799124
[TBL] [Abstract][Full Text] [Related]
3. Network-based approaches elucidate differences within APOBEC and clock-like signatures in breast cancer.
Kim YA; Wojtowicz D; Sarto Basso R; Sason I; Robinson W; Hochbaum DS; Leiserson MDM; Sharan R; Vadin F; Przytycka TM
Genome Med; 2020 May; 12(1):52. PubMed ID: 32471470
[TBL] [Abstract][Full Text] [Related]
4. Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy
Denkert C; Untch M; Benz S; Schneeweiss A; Weber KE; Schmatloch S; Jackisch C; Sinn HP; Golovato J; Karn T; Marmé F; Link T; Budczies J; Nekljudova V; Schmitt WD; Stickeler E; Müller V; Jank P; Parulkar R; Heinmöller E; Sanborn JZ; Schem C; Sinn BV; Soon-Shiong P; van Mackelenbergh M; Fasching PA; Rabizadeh S; Loibl S
Ann Oncol; 2021 Apr; 32(4):500-511. PubMed ID: 33418062
[TBL] [Abstract][Full Text] [Related]
5. A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity.
McMullin RP; Wittner BS; Yang C; Denton-Schneider BR; Hicks D; Singavarapu R; Moulis S; Lee J; Akbari MR; Narod SA; Aldape KD; Steeg PS; Ramaswamy S; Sgroi DC
Breast Cancer Res; 2014 Mar; 16(2):R25. PubMed ID: 24625110
[TBL] [Abstract][Full Text] [Related]
6. Mutational signatures reveal ternary relationships between homologous recombination repair, APOBEC, and mismatch repair in gynecological cancers.
Farmanbar A; Firouzi S; Kneller R; Khiabanian H
J Transl Med; 2022 Feb; 20(1):65. PubMed ID: 35109853
[TBL] [Abstract][Full Text] [Related]
7. Detection of Molecular Signatures of Homologous Recombination Deficiency in Prostate Cancer with or without BRCA1/2 Mutations.
Sztupinszki Z; Diossy M; Krzystanek M; Borcsok J; Pomerantz MM; Tisza V; Spisak S; Rusz O; Csabai I; Freedman ML; Szallasi Z
Clin Cancer Res; 2020 Jun; 26(11):2673-2680. PubMed ID: 32071115
[TBL] [Abstract][Full Text] [Related]
8. Clinical and genomic characterization of mutational signatures across human cancers.
Liao J; Bai J; Pan T; Zou H; Gao Y; Guo J; Xu Q; Xu J; Li Y; Li X
Int J Cancer; 2023 Apr; 152(8):1613-1629. PubMed ID: 36533638
[TBL] [Abstract][Full Text] [Related]
9. Detecting the mutational signature of homologous recombination deficiency in clinical samples.
Gulhan DC; Lee JJ; Melloni GEM; Cortés-Ciriano I; Park PJ
Nat Genet; 2019 May; 51(5):912-919. PubMed ID: 30988514
[TBL] [Abstract][Full Text] [Related]
10. Influence network model uncovers relations between biological processes and mutational signatures.
Amgalan B; Wojtowicz D; Kim YA; Przytycka TM
Genome Med; 2023 Mar; 15(1):15. PubMed ID: 36879282
[TBL] [Abstract][Full Text] [Related]
11. The Mutational Signature Comprehensive Analysis Toolkit (musicatk) for the Discovery, Prediction, and Exploration of Mutational Signatures.
Chevalier A; Yang S; Khurshid Z; Sahelijo N; Tong T; Huggins JH; Yajima M; Campbell JD
Cancer Res; 2021 Dec; 81(23):5813-5817. PubMed ID: 34625425
[TBL] [Abstract][Full Text] [Related]
12. Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas.
Li H; Tu J; Zhao Z; Chen L; Qu Y; Li H; Yao H; Wang X; Lee DF; Shen J; Wen L; Huang G; Xie X
Theranostics; 2020; 10(21):9477-9494. PubMed ID: 32863940
[No Abstract] [Full Text] [Related]
13. Elevated APOBEC mutational signatures implicate chronic injury in etiology of an aggressive head-and-neck squamous cell carcinoma: a case report.
Patel J; den Breems NY; Tuluc M; Johnson J; Curry JM; South AP; Cho RJ
J Med Case Rep; 2021 Apr; 15(1):252. PubMed ID: 33926553
[TBL] [Abstract][Full Text] [Related]
14. Analysis of mutational signatures with yet another package for signature analysis.
Hübschmann D; Jopp-Saile L; Andresen C; Krämer S; Gu Z; Heilig CE; Kreutzfeldt S; Teleanu V; Fröhling S; Eils R; Schlesner M
Genes Chromosomes Cancer; 2021 May; 60(5):314-331. PubMed ID: 33222322
[TBL] [Abstract][Full Text] [Related]
15. ATR Inhibitor Synergizes PARP Inhibitor Cytotoxicity in Homologous Recombination Repair Deficiency TK6 Cell Lines.
Wikiniyadhanee R; Lerksuthirat T; Stitchantrakul W; Chitphuk S; Takeda S; Dejsuphong D
Biomed Res Int; 2023; 2023():7891753. PubMed ID: 36794257
[TBL] [Abstract][Full Text] [Related]
16. Analysis of 7,815 cancer exomes reveals associations between mutational processes and somatic driver mutations.
Poulos RC; Wong YT; Ryan R; Pang H; Wong JWH
PLoS Genet; 2018 Nov; 14(11):e1007779. PubMed ID: 30412573
[TBL] [Abstract][Full Text] [Related]
17. Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor.
Tymon-Rosario JR; Manara P; Manavella DD; Bellone S; Hartwich TMP; Harold J; Yang-Hartwich Y; Zipponi M; Choi J; Jeong K; Mutlu L; Yang K; Altwerger G; Menderes G; Ratner E; Huang GS; Clark M; Andikyan V; Azodi M; Schwartz PE; Alexandrov LB; Santin AD
Gynecol Oncol; 2022 Jul; 166(1):117-125. PubMed ID: 35599167
[TBL] [Abstract][Full Text] [Related]
18. Integrated, Integral, and Exploratory Biomarkers in the Development of Poly(ADP-Ribose) Polymerase Inhibitors.
Konecny GE; Chander C; Zhang L
Cancer J; 2021 Nov-Dec 01; 27(6):482-490. PubMed ID: 34904811
[TBL] [Abstract][Full Text] [Related]
19. Unraveling most abundant mutational signatures in head and neck cancer.
Plath M; Gass J; Hlevnjak M; Li Q; Feng B; Hostench XP; Bieg M; Schroeder L; Holzinger D; Zapatka M; Freier K; Weichert W; Hess J; Zaoui K
Int J Cancer; 2021 Jan; 148(1):115-127. PubMed ID: 32930393
[TBL] [Abstract][Full Text] [Related]
20. Identification of Somatically Acquired
Vidula N; Dubash T; Lawrence MS; Simoneau A; Niemierko A; Blouch E; Nagy B; Roh W; Chirn B; Reeves BA; Malvarosa G; Lennerz J; Isakoff SJ; Juric D; Micalizzi D; Wander S; Spring L; Moy B; Shannon K; Younger J; Lanman R; Toner M; Iafrate AJ; Getz G; Zou L; Ellisen LW; Maheswaran S; Haber DA; Bardia A
Clin Cancer Res; 2020 Sep; 26(18):4852-4862. PubMed ID: 32571788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
